Evidence map›Paper›PMID 34206601›Full record

ArticleMolecules (Basel, Switzerland)2021

Identification and Study of Biomarkers from Novichok-Inhibited Butyrylcholinesterase in Human Plasma.

Woo-Hyeon Jeong, Jin-Young Lee, Kyoung-Chan Lim, Hyun-Suk Kim

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Precisely predicting theScientific reports · 2022
    Article
  5. Article
  6. Recent research on Novichok.Archives of toxicology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Woo-Hyeon JeongAgency for Defense Development (ADD), P.O. Box 35, Yuseong-gu, Daejeon 34186, Korea.ORCID 0000-0001-9370-0644
Jin-Young LeeAgency for Defense Development (ADD), P.O. Box 35, Yuseong-gu, Daejeon 34186, Korea.ORCID 0000-0003-3613-8661
Kyoung-Chan LimAgency for Defense Development (ADD), P.O. Box 35, Yuseong-gu, Daejeon 34186, Korea.
Hyun-Suk KimAgency for Defense Development (ADD), P.O. Box 35, Yuseong-gu, Daejeon 34186, Korea.ORCID 0000-0002-8145-3735
Agency for Defense Development · KR

Funding

Agency for Defense Development 912709201
6 · The paper itself

Abstract

To identify biomarkers of ethyl (1-(diethylamino)ethylidene)phosphoramidofluoridate (A234)- or methyl (1-(diethylamino)ethylidene)phosphoramidofluoridate (A232)-inhibited butyrylcholinesterase (BChE), we investigated nonapeptide adducts containing the active site serine, which plays a key role in enzyme activity, using LC-MS/HRMS. Biomarkers were acquired as expected, and they exhibited a significant amount of fragment ions from the inhibiting agent itself, in contrast to the MS2 spectra of conventional nerve agents. These biomarkers had a higher abundance of [M+2H]

Indexed as

Nerve AgentsOrganophosphatesPlasmaBiomarkersButyrylcholinesteraseCholinesterase InhibitorsHumansBCHE protein, humanBiomarkersButyrylcholinesteraseCholinesterase InhibitorsNerve AgentsnovichokOrganophosphateschemical warfare agentsLC-MS/MSnerve agentNovichok

Identifiers

PMID34206601
PMCPMC8270327
OpenAlexW3176026629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.